Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2007, No. 6


Vera-Lastra OL, Medina-García G, Guadalupe-Reséndiz-Pérez L, Ángeles-Garay U, Torres-Ambriz P, Jara LJ
Prevalencia de hipotiroidismo y anticuerpos antitiroglobulina en pacientes mexicanos con esclerosis sistémica
Gac Med Mex 2007; 143 (6)

Idioma: Español
Referencias bibliográficas: 40
Paginas: 471-475
Archivo PDF: 55.78 Kb.


Texto completo




RESUMEN

Objetivo: Investigar la prevalencia de hipotiroidismo y anticuerpos antitiroglobulina (AATg) en pacientes mexicanos con esclerosis sistémica (ES).
Material y métodos: Se estudió la función tiroidea en pacientes con ES y controles. Se les determinaron los niveles séricos de triyodotironina, tiroxina, hormona estimulante de la tiroides (TSH) y AATg.
Resultados: Fueron 110 pacientes (106 mujeres y 4 hombres), edad promedio de 48.1 ± 28.5 años, versus 80 controles (76 mujeres y 4 hombres), edad promedio 47.5 ± 28.8 años. El hipotiroidismo clínico se encontró en 19% de pacientes con ES y en 1.3% de los controles (p ‹ 0.01). Las medianas respectivamente de triyodotironina en ES y controles fueron: 82 versus 160 ng/dl, p ‹ 0.01; tiroxina 5.4 versus 7 ng/dl, p ‹ 0.01; TSH 8.2 versus 1.1 µUI/ml, p ‹ 0.001. El hipotiroidismo subclínico se observó en 35% de los pacientes con ES y en 0% de los controles. Los valores de TSH en ES y en controles fueron 7.2 versus 1.2 µUI/ml, p ‹ 0.01; triyodotironina 116 versus 160 ng/dl, p ns; tiroxina 7 versus 7 ng/dl, p ns, respectivamente. Los AATg estuvieron presentes en 54% de los pacientes y 2.5% en el grupo control, p ‹ 0.01.
Conclusiones: Los pacientes con ES presentan elevada prevalencia de hipotiroidismo, especialmente subclínico, por lo que debe investigarse la función tiroidea para iniciar tratamiento oportuno.


Palabras clave: Esclerosis sistémica, hipotiroidismo clínico, hipotiroidismo subclínico, anticuerpos antitiroglobulina, hormonas tiroideas.


REFERENCIAS

  1. Seibold JR. Scleroderma. En: Kelly WN, Harris ED Jr. Ruddy S, Sledge CB, editors. Textbook of rheumatology. 5th ed. Philadelphia: W.B. Saunders; 1997. pp. 1133-1162.

  2. D’Angelo WA, Fries JF, Masi AT, Shulman LE. Pathologic observations in systemic sclerosis (scleroderma). A study of fifty-eight autopsy cases and fiftyeight matched controls. Am J Med 1969;46:428-440.

  3. Gordon MB, Klein I, Dekker A, Rodnan GP, Medsger TA Jr. Thyroid disease in progressive systemic sclerosis: increased frequency of glandular fibrosis and hypothyroidism. Ann Intern Med 1981;95:431-435.

  4. Kahl LE, Medsger TA Jr, Klein I. Prospective evaluation of thyroid function in patients with systemic sclerosis (scleroderma). J Rheumatol 1986;13:103-107.

  5. Biro E, Szekanecz Z, Czirjak L, Danko K, Kiss E, Szabo NA, et al. Association of systemic and thyroid autoimmune diseases. Clin Rheumatol 2006;25:240-245.

  6. Besancon MF, Guzman L, Grisanti M, Basualdo J, Alvarado MA, Rendic O, et al. Thyroid disease in progressive systemic sclerosis. Rev Med Chil 1990;118:388-391.

  7. De Keyser L, Narhi DC, Furst DE, Huberman AK, Ross R, Clements J, et al. Thyroid dysfunction in a prospectively followed series of patients with progressive systemic sclerosis. J Endocrinol Invest 1990;13:161-169.

  8. Innocencio RM, Romaldini JH, Ward LS. Thyroid autoantibodies in autoimmune diseases. Medicina 2004;64:227-230.

  9. Molteni M, Barili M, Eisera N, Scrofani S, Mascagni B, Zulian C, et al. Antithyroid antibodies in Italian scleroderma patients: association of anti-thyroid peroxidase (anti-TPO) antibodies with HLA-DR15. Clin Exp Rheumatol 1997;15:529-534.

  10. Masi AT, Rodnan GP, Medsger TA Jr. Preliminary criteria for classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:581-590.

  11. Vitali C, Bombardieri S, Moutsopoulus HM, Balestrieri G, Bencivelli W, Bernstein RM, et al. Preliminary criteria for the classification of Sjogren syndrome. Results of a prospective concerted action supported by European community. Arthritis Rheum 1993; 36:340-347.

  12. Martínez-Salgado H, Castañeda-Limones R, Lechuga-Martínez del Campo D, Romero-Hernández RI, Orozco-López M, Rivera-Dommarco J, et al. Deficiencia de yodo y otros posibles bociógenos en la persistencia del bocio endémico en México. Gac Med Mex 2002;138:149-156.

  13. Pretell EA, Aguirre A, Güell R, Canelos P, Higa AM, Cevallos JL, et al. Consenso sobre los desórdenes por deficiencia de yodo en Latinoamérica. Criterios de evaluación y monitoreo para su erradicación sostenida. Rev Cub Endocrinol 1999;10:146-156.

  14. Ghayad E, Tohme A, Haddad F, Haddad C, Choueiry R. Scleroderma with anomalies of the thyroid function. 7 cases. Ann Med Interne 1997;148:307-310.

  15. Vera-Lastra OL, Jara LJ. Alteraciones endocrinas en la esclerosis sistémica. Reumatol Clin 2006;2(Supl 3):37-41.

  16. Shahin AA, Abdoh S, Abdelrazik M. Prolactin and thyroid hormones in patients with systemic sclerosis: correlation with disease manifestations and activity. Z Rheumatol 2002;61:903-909.

  17. Punzi L, Betterle C. Chronic autoimmune thyroiditis and rheumatic manifestations. Joint Bone Spine 2004;71:275-283.

  18. Yamamoto M, Fuwa Y, Chimori K, Yamakita N, Sakata S. A case of progressive systemic sclerosis (PSS) with silent thyroiditis and anti-bovine thyrotropin antibodies. Endocrinol Jpn 1991;38:265-270.

  19. Punzi L, Betterle C. Chronic autoimmune thyroiditis and rheumatic manifestations. Joint Bone Spine 2004 ;71:275-283.

  20. Sanchez-de Rivera JM, Barbado-Hernández FJ, Vázquez-Rodríguez JJ, Gil-Aguado A, García-Puig J, Viguer-García Moreno JM. Scleroderma with traces of disseminated lupus erythematosus associated with Hashimoto’s thyroiditis and papillary carcinoma of the thyroid gland (author’s transl). Med Clin 1979;73:342-346.

  21. Stagi S, Giani T, Simonini G, Falcini F. Thyroid function, autoimmune thyroiditis and coeliac disease in juvenile idiopathic arthritis. Rheumatology 2005;44:517-20. Epub 2005 Feb 3.

  22. Farzati B, Mazziotti G, Cuomo G, Ressa M, Sorvillo F, Amato G, et al. Hashimoto’s thyroiditis is associated with peripheral lymphocyte activation in patients with systemic sclerosis. Clin Exp Rheumatol 2005;23:43-49.

  23. Szyper-Kravitz M, Marai I, Shoenfeld Y. Coexistence of thyroid autoimmunity with other autoimmune diseases: friend or foe? Additional aspects on the mosaic of autoimmunity. Autoimmunity 2005;38:247-255.

  24. Ramos-Casals M, García-Carrasco M, Cervera R, Gaya J, Halperin I, Ubieto I, et al. Thyroid disease in primary Sjögren syndrome. Study in a series of 160 patients. Medicine 2000;79:103-108.

  25. Vanderpump MP, Tunbridge WM, French JM. The incidence of thyroid disorder in the community: a twenty-year follow-up of the Whickham survey. Clin Endocrinol 1995;43:55-68.

  26. Cooper DS. Subclinical hypothyroidism. N Engl J Med 2001;345:260-265.

  27. Gartner R. Subclinical hypothyroidism -does it have to be treated? MMW Fortschr Med 2004;146:37-39.

  28. Mann K, Janssen OE. Subclinical hypothyroidism -what level of TSH is an indication for substitution? MMW Fortschr Med 2006;148:26-29.

  29. Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function and quality of life in subclinical hypothyroidism: randomised, crossover trial. J Clin Endocrinol Metab 2007 Feb 13 (Epub ahead of print).

  30. Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular, and death. Arch Inter Med 2005;165:2460-2466.

  31. Crapo LM. Subclinical hypothyroidism and cardiovascular disease. Arch Inter Med 2005;165:2451-2452.

  32. Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feedema P, et al. Subclinical thyroid dysfunction as risk factor for cardiovascular disease. Arch Inter Med 2005;165:2467-2472.

  33. Kotyla PJ, Lewicki M, Kucharz EJ. Hypothyroidism contributes to increased triglyceride levels among patients with systemic sclerosis. J Rheumatol 2006;33:827.

  34. Franzoni F, Galetta F, Fallahi P, Tocchini L, Merico G, Braccini L, et al. Effect of L-thyroxine treatment on left ventricular function in subclinical hypothyroidism. Biomed Pharmacother 2006;60:431-436.

  35. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N, et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005;112:3337-3347.

  36. Iqbal A, Jorde R, Figenschau Y. Serum lipid levels in relation to serum thyroidstimulating hormone and the effect of thyroxine treatment on serum lipid levels in subjects with subclinical hypothyroidism: the Tromso Study. J Intern Med 2006;260:53-61.

  37. Zhu DF, Wang ZX, Zhang DR, Pan ZL, He S, Hu XP, et al. fMRI revealed neural substrate for reversible working memory dysfunction in subclinical hypothyroidism. Brain 2006;129(Pt 11):2923-2930.

  38. Sait Gonen M, Kisakol G, Savas Cilli A, Dikbas O, Gungor K, Inal A, et al. Assessment of anxiety in subclinical thyroid disorders. Endocr J 2004;51:311-315.

  39. Walker SA. Impared hypothalamic function, prolactinomas, and autoimmune diseases. J Rheumatol 2006;33:1036-1037.

  40. Vera-Lastra O, Jara LJ, Medina G, Rojas JL, Velásquez F, Ariza R, et al. Functional hyperprolactinemia and hypophyseal microadenoma in systemic sclerosis. J Rheumatol 2006;33:1108-1112.



>Revistas >Gaceta Médica de México >Año2007, No. 6
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019